2-(6-carboxyhexyl)cyclopentanone hexylhydrazone: A potent inhibitor of the blood platelet cyclo-oxygenase

Previous studies have demonstrated that 13-azaprostanoic acid (13-APA) is a potent and specific antagonist of thromboxane A₂/prostaglandin H₂ (TXA₂/PGH₂) at the platelet receptor level. In the present study we evaluated the effects of a new azaprostanoid, 2-(6-carboxyhexyl) cyclopentanone hexylhydrazone (CPH), on human platelet function. This hydrazone was found to completely inhibit arachidonic acid (AA)-induced platelet aggregation at 1 uM CPH. On the other hand, CPH was not an effective inhibitor of PGH₂-induced aggregation. Furthermore, 100 uM CPH was completely ineffective in blocking platelet aggregation stimulated by adenosine diphosphate (ADP) or the stable prostaglandin endoperoxide analog U46619 (which presumably acts at the TXA₂/PGH₂ receptor). Measurement of platelet thromboxane B₂ (TXB₂) production demonstrated that the primary site-of-action of CPH is at the cyclo-oxygenase level. Thus, CPH inhibited TXB₂ formation from AA in a dose-dependent manner (0.1 uM–100 uM CPH)². In contrast, CPH blocked TXB₂ production from PGH₂ only at the highest CPH concentration tested, i.e., 100 uM. These results indicate that relative to 13-APA, addition of a second nitrogen at C₁₄ and a double bond between the 12- and 13- positions results in a loss of receptor activity but produces a high affinity for the platelet cyclo-oxygenase.     

Binding of a thromboxane A2/prostaglandin H2 agonist [H]U46619 to washed human platelets

The binding characteristics of [³H]U46619 to washed human platelets were studied. [³H]U46619 binding to washed human platelets was saturable and displaceable. Kinetic studies yielded a K_d of 11 ± 4 nM (n=4). Scatchard analysis of equilibrium binding studies revealed one class of high affinity binding sites with a K_d of 20 ± 7nM and a B_max of 9.1 ± 2.3 fmole/10⁷ platelets (550 ± 141 binding sites per platelet) (n=4). A number of compounds that act as either agonists or antagonists of the TXA₂/PGH₂ receptor were tested for their ability to inhibit the binding of [³H]U46619 to washed human platelets. The K_ds of the agonists and antagonists were similar to their potencies to induce or inhibit platelet aggregation. These data provide some evidence that [³H]U46619 binds to the putative human platelet TXA₂/PGH₂ receptor.     

Synthesis of [17,18-3H] trans-13-azaprostanoic acid. A labeled probe for the PGH2/TXA2 receptor

Because of its highly unstable nature, TXA2, produced by platelet metabolism of arachidonic acid, does not lend itself to use as a receptor probe for its own receptor. As such, the stable TXA2/PGH2 antagonist, trans-13-azaprostanoic acid (trans-13-APA, 12b), was prepared as the [17, 18 3H] derivative [( 3H] trans-13-APA, 12c) to study this receptor and to better evaluate the mechanism of action of these azaprostanoids. Tritiated trans-13-APA, 12c, was prepared in nearly theoretical specific activity (57 Ci/mmole) from (17Z)-trans-13-azaprost-17-enoic acid (11b) by catalytic tritiation. The unsaturated 11b was prepared by condensation of cis-7-amino-3-heptene (8) with 2-(6-carboxyhexyl) cyclopentanone (9), NaBH4 reduction, chromatography, and hydrolysis of the trans isomer so isolated. The olefins 11a and b were also of biochemical interest because of the unsaturation in the lower side chain. The presence of similar unsaturation in PGH3(4) and TXA3 (3) renders these prostaglandins inactive as proaggregatory agents. Evaluation of the antiaggregatory activity of 11a and b indicated it to be about the same potency in inhibiting human platelet aggregation as the parent cis and trans-13-APAs, suggesting that introduction of a double bond at the 17 position in platelet prostaglandin antagonists is unlikely to result in enhanced antiplatelet activity.     

Preparation and biochemical properties of PGH3

PGH₃ was biosynthesised from all-cis-5,8,11,14,17-eicosapentaenoic acid (20:5ω3) by an acetone-pentane powder of ram seminal vesicles and its structure was confirmed by GLC-MS after its reduction to PGF₃α. PGH₃ was transformed by horse platelet microsomes to TXB₃, and by aortic microsomes to Δ¹⁷-6-keto-PGF₁α. The structures of these compounds were confirmed by GLC-MS.     

Involvement of aquaporin in thromboxane A2 receptor-mediated, G12/13/RhoA/NHE-sensitive cell swelling in 1321N1 human astrocytoma cells

The physiological role of the thromboxane A₂ (TXA₂) receptor expressed on glial cells remains unclear. We previously reported that 1321N1 human astrocytoma cells pretreated with dibutyryl cyclic AMP (dbcAMP) became swollen in response to U46619, a TXA₂ analogue. In the present study, we examined the detailed mechanisms of TXA₂ receptor-mediated cell swelling in 1321N1 cells. The cell swelling caused by U46619 was suppressed by expression of p115-RGS, an inhibitory peptide of Gα_12/13 pathway and C3 toxin, an inhibitory protein for RhoA. The swelling was also inhibited by treatment with Y27632, a Rho kinase inhibitor and 5-(ethyl-N-isopropyl)amiloride (EIPA), a Na⁺/H⁺-exchanger inhibitor. Furthermore, cell swelling was suppressed by the pretreatment with aquaporin inhibitors mercury chloride or phloretin in a concentration-dependent manner, suggesting that aquaporins are involved in U46619-induced 1321N1 cell swelling. In fact, U46619 caused [³H]H₂O influx into the cells, which was inhibited by p115-RGS, C3 toxin, EIPA, mercury chloride and phloretin. This is the first report that the TXA₂ receptor mediates water influx through aquaporins in astrocytoma cells via TXA₂ receptor-mediated activation of Gα_12/13, Rho A, Rho kinase and Na⁺/H⁺-exchanger.     

Effects of all CIS-5, 8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation

In human platelet-rich plasma (PRP) eicosapentaenoic acid (EPA) inhibited platelet aggregation induced by a stable analogue of PGH₂ (U46619), arachidonic acid, collagen or ADP. EPA was more potent than oleic, linoleic, α-linolenic or γ-linolenic acids. In aspirin-treated platelets, aggregation induced by U46619 was inhibited to a similar extent by arachidonic acid or by EPA over a range of concentrations of 0.05–0.3 mM. EPA incubated with PRP did not induce the generation of a thromboxane (TXA)-like activity; indeed it prevented the formation of TXA₂ induced by arachidonic acid or by collagen. The anti-aggregatory activity of EPA was not influenced by inhibitors of cyclo-oxygenase and lipoxygenase. The anti-aggregatory action of EPA may be caused by a rapid occupancy by EPA of TXA₂/PGH₂ “receptors” on platelet membrane as well as by a slower displacement of arachidonic acid from platelet phospholipids by chemically unchanged molecules of EPA.Not all samples of PRP were irreversibly aggregated by PGH₂, but in those that were, PGH₃ also induced an immediate dose-dependent but reversible aggregation. After a 4 min incubation of non-aggregating doses of PGH₂ or PGH₃ (100–300 nM) with PRP a stable anti-aggregatory compound was detected. The inhibitory activity produced from PGH₃ was apparently more potent (ca 10 times) than that obtained from PGH₂. The anti-aggregating compounds were identified by TLC and GLC-MS as PGD₂ and PGD₃. The apparent difference of potency between PGD₂ and PGD₃ was attributed to the concurrent production of PGE₂ and PGE₃. PGE₂ prevented the inhibitory effect of PGD₂ whereas PGE₃ did not affect the activity of PGD₃.It is concluded that one of the reasons for the low incidence of myocardial infarction in Eskimos could be that the pro-aggregatory arachidonic acid is replaced in their phospholipids by the anti-aggregatory EPA.     

Prostaglandins H1 and H2. Convenient biochemical synthesis and isolation. Further biological and spectroscopic characterization

An easy biochemical preparation of the prostaglandin endoperoxides, PGH₁ and PGH₂, is described. Both of the endoperoxides are potent contractors of isolated gerbil colon smooth muscle. Contracture with PGH₂ is about equal to that caused by the standard, PGE₁, while contracture with PGH₁ is about half of that caused by PGE₁. PGH₁ was found to inhibit platelet aggregation induced by PGH₂ and is about 1/10 as potent a stimulator of cAMP accumulation as is PGE₁. The mass spectra of the methyl esters of both PGH₁ and PGH₂ were obtained, as were the infrared spectra of the two compounds. The nuclear magnetic resonance spectrum of PGH₂ is characterized by signals at 4.58 δ and 4.47 δ for the C-9 and C-11 protons, respectively.     

Synthesis and multinuclear magnetic resonance spectroscopy of the novel ionic Pt(II) mixed-ligands complexes cis- and trans-[Pt(amine)2(pyrimidine)2](NO3)2

Novel ionic mixed-ligands complexes of the types cis- and trans-[Pt(amine)₂(pm)₂](NO₃)₂ (where pm = pyrimidine) were synthesized and studied in the solid state by IR spectroscopy and in aqueous solution by multinuclear (¹⁹⁵Pt, ¹H and ¹³C) magnetic resonance spectroscopy. The results of the solution NMR characterization have shown that the isolated compounds are pure. In ¹⁹⁵Pt NMR, the cis RNH₂ complexes were observed at slightly lower fields (ave. −2441 ppm) than the equivalent trans analogues (ave. −2448 ppm). For Me₂NH, the difference between the two isomers is larger (29 ppm). The complexes are observed at lower fields (difference of 100 ppm) than the corresponding [Pt(amine)₄]²⁺ complexes, which might indicate the presence of π-backdonation in the Pt-pm bond. In ¹H NMR, the coupling constants ³J(¹⁹⁵Pt-¹H_amine) are larger in the cis compounds (38-48 Hz) than in the trans analogues (30-36 Hz). The ³J(¹⁹⁵Pt-¹H_pm) values are also larger for the cis isomers. In ¹³C NMR spectroscopy, the coupling constants ³J(¹⁹⁵Pt-¹³C_amine) are 36 Hz (ave.) for the cis complexes and 26 Hz (ave.) for the trans isomers, while the ²J(¹⁹⁵Pt-¹³C_amine) are 18 Hz (cis) and 14 Hz (trans), respectively. The ³J(¹⁹⁵Pt-¹³C_5(pm)) values are 36 Hz (cis) and 28 Hz (trans). A few ²J(¹⁹⁵Pt-¹³C_pm) couplings were observed (7-10 Hz).     

Multinuclear NMR study and crystal structures of complexes of the types cis- and trans-Pt(amine)2I2

Complexes of the types cis- and trans-Pt(amine)₂I₂ were studied by spectroscopic methods, especially by multinuclear NMR spectroscopy. In ¹⁹⁵Pt NMR, the cis diiodo compounds with primary amines were observed between −3342 and −3357 ppm in acetone, while the trans compounds were found between −3336 and −3372 ppm. For the secondary amines, the chemical shifts were observed at lower fields. In ¹H NMR, the trans complexes were observed at higher fields than the cis compounds, while in ¹³C NMR, the reverse was observed. The ²J(¹⁹⁵Pt-¹H) and ³J(¹⁹⁵Pt-¹H) coupling constants are larger for the cis compounds (ave. 67 and 45 Hz, respectively) than for the trans isomers (ave. 59 and 38 Hz). In ¹³C NMR, the values of ²J(¹⁹⁵Pt-¹³C) and ³J(¹⁹⁵Pt-¹³C) were also found to be larger for the cis complexes (ave. 17 and 39 Hz versus 11 and 28 Hz). There seems to be a slight dependence of the pK_a values of the protonated amines or the proton affinity in the gas phase with the δ(Pt) chemical shifts. The crystal structures of eight diiodo complexes were determined. These compounds are cis-Pt(CH₃NH₂)₂I₂, cis-Pt(n-C₄H₉NH₂)₂I₂, cis-Pt(Et₂NH)₂I₂, trans-Pt(n-C₃H₇NH₂)₂I₂, trans-Pt(iso-C₃H₇NH₂)₂I₂, trans-Pt(n-C₄H₉NH₂)₂I₂, trans-Pt(t-C₄H₉NH₂)₂I₂ and trans-Pt(Me₂NH)₂I₂. The Pt-N bond distances located in trans position to the iodo ligands were compared to those located in trans position to the amines. The Pt-N bond in cis-Pt(Et₂NH)₂I₂ are much longer than the others, probably caused by the steric hindrance of the two very bulky ligands located in cis positions.     

Prostaglandin F2α antagonizes thromboxane A2-induced human platelet aggregation

The effects of prostaglandin F_2α on human blood platelet function were investigated. PGF_2α at 15 μM completely blocked platelet aggregation induced by 500 μM arachidonic acid or 3 μM U46619 but had no effect on aggregatin induced by 7.5 μM ADP. A similar specificity of action was not obtained with either PGI₂ or PGE₂. Thus concentrations of PGI₂ (3 nM) or PGE₂ (20 μ M) which inhibited U46619-induced aggregation by 100% also blocked ADP-stimulated aggregation.The inhibitory properties of PGF_2α were not related to increases in platelet cAMP, since direct measurement of intracellular cAMP revealed that 15 μ M PGF_2α produced no substantial change in cAMP levels. This finding was in direct contrast to results obtained using either PGI₂ or PGE₂. Both PGI₂ (3 nM) and PGE₂ (20 μ M) induced significant increases in platelet cAMP levels.The possibility that PGF_2α directly interacts at the platelet TXA₂/PGH₂ receptor was investigated by measuring [³H]PGF_2α binding to isolated platelet membranes. It was found that [³H] PGF_2α binding reached equilibrium within 30 min at room temperature and could be 90% displaced by addition of 1000 fold excess of unlabelled PGF_2α. Furthermore, when 1000 fold excess of either the TXA₂/PGH₂ “mimetic” U46619 or the TXA₂/PGH₂ antagonist 13-azaprostanoic acid was added, specific [³H] PGF_2α binding was displaced by 95% and 85% respectively. In contrast, the same molar excess of 6-keto-PGF_1α, azo analog 1, or TXB₂, caused displacement of only 15%, 20% or 25% of the [³H] PGF_2α binding. Scatchard analysis indicated that [³H] PGF_2α has two binding sites; i.e., a high affinity binding site with an apparent Kd of 50 nM and a low affinity binding site with apparent Kd of 320 nM. These results suggest that the selective inhibition by PGF_2α of AA or U46619-induced aggregation may be mediated through interaction at the platelet TXA₂/PGH₂ receptor.     

Synthesis and multinuclear magnetic resonance spectroscopy of the novel ionic Pt(II) mixed-ligands complexes cis- and trans-[Pt(pyrazine)2(Ypy)2](NO3)2 where Ypy = pyridine derivative

Novel ionic mixed-ligands complexes of the types cis- and trans-[Pt(pz)₂(Ypy)₂](NO₃)₂ (where Ypy is a pyridine derivative and pz = pyrazine) were synthesized and studied mainly in the solid state by IR spectroscopy and in aqueous solution by multinuclear (¹⁹⁵Pt, ¹H and ¹³C) magnetic resonance spectroscopy. The trans isomers with ligands containing a methyl group in ortho position on the pyridine ring could not be synthesized. The results of the solution NMR characterization have shown that the isolated compounds are pure. In ¹⁹⁵Pt NMR, the cis complexes containing a methyl group in ortho positions were observed at lower field (average −2337 ppm) than the other cis compounds (average −2427 ppm), which is explained by the solvent effect. The trans isomers were observed at very slightly lower fields (average −2422 ppm) than the equivalent cis complexes (average −2427 ppm). In ¹H NMR, the coupling constants ³J(¹⁹⁵Pt-¹H_Ypy) and ³J(¹⁹⁵Pt-¹H_pz) are larger in the cis compounds (∼40 Hz) than in the trans complexes (∼31 Hz). A few ⁴J(¹⁹⁵Pt-¹H_pz) were observed (∼16 Hz). In ¹³C NMR spectroscopy, the coupling constants ³J(¹⁹⁵Pt-¹³C_pz) and ³J(¹⁹⁵Pt-¹³C_Ypy) are also larger in the cis configuration (∼30 and ∼38 Hz, respectively) than in the trans isomers (∼20 Hz). One ⁴J(¹⁹⁵Pt-¹³C_pz) could be calculated (17 Hz). The presence of the syn and anti rotamers were observed in all the cis complexes containing a pyridine derivative with a -CH₃ group in ortho position. They were observed in ¹⁹⁵Pt, ¹H and ¹³C NMR spectroscopy. The proportion of the two rotamers is about 55% and 45%.     

Pharmacophore requirements in new series of pyridazinyl alkanoic acids, N-[(pyridazin-2-yl) alkyl] succinyl and glutaryl amides, inhibitors of thromboxane A2 biosynthesis

New series of 5-benzyl-6-methyl-4-oxo pyridazin-2-yl alkanoic acids, N-[(pyridazin-2-yl)alkyl] succinyl and glutaryl amides have been synthesized and evaluated in vitro as TXA₂ biosynthesis inhibitors. The experiments were carried out using arachidonic acid (32.8 μM) as a substrate and horse platelet microsomes as sources of TXA₂ synthase. The presence of TXB₂, a stable metabolite of TXA₂, was determined by RIA. The potency of active compounds (1.10⁻⁴ < IC 50 < 1.10⁻⁶ M) greatly depends on the length of the chain at the N-2 position on the pyridazine ring. Furthermore, enzyme inhibition in vitro is increased with the presence of a halogen atom on the aromatic moiety of the benzyl group at C-5. Compound 4f having a pentanoic side chain and a 4-fluoro benzyl moiety was the most active derivative with an IC₅₀ value of 6.69 × 10⁻⁶ M. Molecular modelling studies were done on all the synthesized pyridazinones and on prostaglandin H₂ (PGH₂) suggesting spatial features and volumes of TXA₂ synthase pharmacophore mode in these series of derivatives.     

Study of Pt(II)-cyclic amines complexes of the types cis- and trans-Pt(amine)2I2 and cis- and trans-Pt(amine)2(NO3)2 and their aqueous products by

Complexes of the types cis- and trans-Pt(amine)₂I₂ containing cyclic amines were synthesized and studied mainly by IR and multinuclear NMR spectroscopies. The compounds were converted to cis- and trans-Pt(amine)₂(NO₃)₂, which were also investigated. The hydrolysis and the aquation reactions of the latter compounds were then studied in D₂O in different conditions of pH. In acidic medium, the aqueous product is [Pt(amine)₂(D₂O)₂]²⁺ and for a few amines, [Pt(amine)₂(D₂O)(NO₃)]⁺ was detected. In basic pH, the main product is Pt(amine)₂(OD)₂ and Pt(amine)₂(OD)(NO₃) was detected for several compounds. In neutral pH, the cis isomers form between two and four species in fresh solutions. The most shielded species in ¹⁹⁵Pt NMR is the monoaqua-monohydroxo complex cis-[Pt(amine)₂(D₂O)(OD)]⁺ and the less shielded compound is the dihydroxo-bridged dimer [Pt(amine)₂(μ-OD)₂Pt(amine)₂]²⁺, which were observed for all the compounds. For a few amines, the monohydroxo-bridged dimer [Pt(D₂O)(amine)₂(μ-OD)Pt(OD)(amine)₂]²⁺ was detected and for cyclohexylamine, a fourth signal was assigned to a cyclic hydroxo-bridged trimer [(Pt(amine)₂(μ-OD))₃]³⁺. ¹⁹⁵Pt NMR spectroscopy has shown that the concentration of the monomer decreases with time, while the concentration of the dimers increases. Only one product was observed for the trans isomers in neutral pH. The signal was assigned to the monoaqua-monohydroxo species trans-[Pt(amine)₂(D₂O)(OD)]⁺. The ¹³C and ¹H NMR spectra of most of the complexes were measured. All the coupling constants ^2,3J(¹⁹⁵Pt-¹H) and ^2,3J(¹⁹⁵Pt-¹³C) are larger in the cis compounds than in the trans isomers.     

Inhibition of GSH-dependent PGH2 isomerase in mammary adenocarcinoma cells by allicin.

We have reported tha allicin, a constituent of garlic oil, has no effect on the activities of platelet cyclooxygenase or thromboxane synthase, or vascular PGI₂ synthase. The effect of allicin on glutathione (GSH) dependent PGH₂ to PGE₂ isomerase is unknown. We therefore studied the effect of allicin on PGE₂ biosynthesis in a murine mammary adenocarcinoma cell line (No 4526). Intact or sonicated cells were incubated with either ¹⁴C-arachidonic acid (AA) or ¹⁴C-PHG₂, respectively. Following metabolism, products were extracted, separated by TLC and analyzed by radiochromatographic scan. PGE₂ was predominantly formed with minimal amounts of PGF_2α and PGD₂. Formation of 6-keto-PGF_1α or TXB₂ was not detected indicating the absence of TXA₂ and PGI₂ synthase activity. Indomethacin and ibuprofen inhibited the PGE₂ formation (p < 0.05). The enzymatic PGE₂ formation in sonicates was blocked by depletion of the cellular non-protein thiols by buthionine sulfoximine and was shown to be dependent on GSH. Allicin, over the range of 10–1000 μM, inhibited the formation of PGE₂ in cells exposed to 2.0 μM ¹⁴C-AA for 20 min. and in sonicated cells incubated with 20.0 μM ¹⁴C-PGH₂ for 2 min (p < 0.05). Allicin did not alter cyclooexygenase-mediated oxygen utilization in ram seminal vessicle microsomes, suggesting that allicin selectively inhibits the GSH-dependent PGH₂ to PGE₂ isomerase in this adenocarcinoma cell line.     

The association of thromboxane A2 receptor with lipid rafts is a determinant for platelet functional responses

We have investigated the presence of thromboxane A₂ (TXA₂) receptor associated with lipid rafts in human platelets and the regulation of platelet function in response to TXA₂ receptor agonists when lipid rafts are disrupted by cholesterol extraction. Platelet aggregation with TXA₂ analogs U46619 and IBOP was almost blunted in cholesterol-depleted platelets, as well as α_IIbβ₃ integrin activation and P-selectin exposure. Raft disruption also inhibited TXA₂-induced cytosolic calcium increase and nucleotide release, ruling out an implication of P2Y₁₂ receptor. An important proportion of TXA₂ receptor (40%) was colocalized at lipid rafts. The presence of the TXA₂ receptor associated with lipid rafts in platelets is important for functional platelet responses to TXA₂.     

Synthesis, structure and properties of TTF-carboxylate bridged paddlewheel dirhodium complexes, Rh2(BuCO2)3(TTFCO2) and Rh2(BuCO2)2(TTFCO2)2

Reaction of tetrathiafulvalene carboxylic acid (TTFCO₂H) with paddlewheel dirhodium complex Rh₂(Bu^tCO₂)₄ yielded TTFCO₂-bridged complexes Rh₂(Bu^tCO₂)₃(TTFCO₂) (1) and cis- and trans-Rh₂(Bu^tCO₂)₂(TTFCO₂)₂ (cis- and trans-2). Their triethylamine adducts [1(NEt₃)₂] and cis-[2(NEt₃)₂] were purified and isolated with chromatographic separation, and characterized with single crystal X-ray analysis. Trans-[2(NEt₃)₂] is not completely separated from a mixture of cis- and trans-[2(NEt₃)₂], but its single crystals were obtained from a solution of the mixture. A three-step quasi-reversible oxidation process was observed for 1 in MeCN. The first two steps correspond to the oxidation of the TTFCO₂ moiety and the last one is the oxidation of the Rh₂ core. The oxidation of cis-2 is observed as a two-step process with very similar E_1/2 values to those of the first two processes for 1. Both 1⁺ and cis-2²⁺ in MeCN at room temperature show isotropic ESR spectra with a g value of 2.008 and a_H = 0.135 mT for two equivalent H atoms and a_H = 0.068 mT for one H atom. The redox and ESR data of cis-2 suggest that the intramolecular interaction between the TTF moieties is very small.     

Structure and reactivity of [Ru(2,3-Medpp)2Cl2]

The structure and reactivity of the complex [Ru(2,3-Medpp)₂Cl₂](PF₆)₂ (2,3-Medpp⁺=2-[2-(1-methylpyridiniumyl)]-3-(2-pyridyl)pyrazine) was investigated by X-ray diffraction (XRD), ¹H NMR, redox, and UV-Vis absorption measurements. X-ray analysis shows that crystals obtained from an acetonitrile-toluene solution contain the trans-Cl₂, trans-pyrazine isomeric form, while ¹H NMR and redox measurements on the main product of the synthetic workup indicate the presence of the trans-Cl₂, cis-pyrazine isomer. In the dark at 70 °C, the complex [Ru(2,3-Medpp)₂Cl₂]²⁺ reacts slowly in acetonitrile isomerizing to the cis-[Ru(2,3-Medpp)₂(CH₃CN)Cl]³⁺ species. Under ambient light in the presence of excess AgNO₃ the cis-[Ru(2,3-Medpp)₂(CH₃CN)₂]⁴⁺ species is obtained.     

Synthesis of 5,6-dihydro-4H-1,3-oxazines from neutral and cationic platinum(II) nitrile complexes. X-ray structure of trans-[Pt(CF3){ H2CH2}(PPh3)2]BF4

The 1,3-oxazine complexes cis- and trans-[PtCl₂{ C(R)OCH₂CH₂C}H₂₂] (cis: R=CH₃ (1a), CH₂CH₃ (2a), (CH3)₃C (3a), C₆H₅ (4a); trans:R =CH₃ (1b), C₆H₅ (4b)) were obtained in 51-71% yield by reaction in THF at 0 °C of the corresponding nitrile complexes cis- and trans-[PtCl2(NCR)₂] with 2 equiv. of ⁻OCH₂CH₂CH₂Cl, generated by deprotonation of 3-chloro-1-propanol with n-BuLi. The cationic nitrile complexes trans-[Pt(CF₃)(NCR)(PPh₃)₂]BF₄ (R=CH3, C₆H₅) react with 1 equiv, of ⁻ OCH2CH2CH2Cl to give a mixture of products, including the corresponding oxazine derivatives trans-[Pt(CF₃){ CH₂}(PPh₃)₂]BF₄ (5 and 6), the chloro complex _trans- [Pt(CF₃)Cl(PPh₃)₂] and free oxazine H2. For short reaction times (c. 5–15 min) the oxazine complexes 5 and 6 could be isolated in modest yield (37–49%) from the reaction mixtures and they could be separated from the corresponding chloro complex (yield 40%) by taking advantage of the higher solubility of the latter derivative in benzene. For longer reaction times (> 2 h), trans-[Pt(CF₃)Cl(PPh₃)₂] was the only isolated product. Complex 6 was crystallographically characterized and it was found to contain also crystals of trans- [PtCl{ H₂}(PPh₃)₂]BF₄, which prevented a more detailed analysis of the bond lengths and angles within the metal coordination sphere. The 1,3-oxazine ring, which shows an overall planar arrangement, is characterized by high thermal values of the carbon atoms of the methylene groups indicative of disordering in this part of the molecule in agreement with fast dynamic ring processes suggested on the basis of ¹H NMR spectra. It crystallizes in the trigonal space group P , with a=22.590(4), b=15.970(3) Å, γ=120°, V=7058(1) ų and Z=6. The structure was refined to R=0.059 for 3903 unique observed (I3σ(I)) reflections. A mechanism is proposed for the conversion of nitrile ligands to oxazines in Pt(II) complexes.     

Synthesis and study of Pt(II)-aromatic amines complexes of the types cis- and trans-Pt(amine)2(NO3)2 and cis-Pt(amine)2(R(COO)2)

Complexes of the types cis- and trans-Pt(amine)₂(NO₃)₂ with amines containing a phenyl group were synthesized and studied mainly by IR and multinuclear magnetic resonance spectroscopies. The cis complexes could be synthesized pure only with the amines of the type Ph-R-NH₂ (R = alkyl), while pure trans compounds were synthesized with all the studied amines. In ¹⁹⁵Pt NMR spectroscopy, the dinitrato complexes of the amines Ph-R-NH₂ were observed around −1700 ppm for the cis isomers and at about −1580 for the trans complexes. For the other amines, where a phenyl ring is directly attached to the amino group, the signals were observed at lower fields, −1528 ppm for cis-Pt(PhNH₂)(NO₃)₂ and around −1450 ppm for all the trans isomers. There is a linear relationship between the δ(Pt) of the Pt(amine)₂(NO₃)₂ complexes and the pK_a of the protonated amines. The coupling constants ²J(¹⁹⁵Pt-¹HN) are larger in the cis compounds (ave. 76 Hz) than in the trans isomers (ave. 63 Hz). The complexes cis-Pt(amine)₂(R(COO)₂) with bidentate dicarboxylato ligands were also synthesized and characterized mainly by IR spectroscopy. The compounds apparently decompose in DMF and are too insoluble in other solvents for solution studies.     

Enhancement of PGI2 formation by a new vasodilator, 2-nicotinamidoethyl nitrate in the coupled system of platelets and aortic microsomes

Exogenous arachidonate addition to the coupled system of platelets and aortic microsomes resulted in production of TXA₂ and PGI₂ (detected as the stable degradation products, TXB₂ and 6-keto PGF_1α, respectively). Imidazole, papaverine and dipyridamole increased PGI₂ and decreased TXA₂ in the coupled system. All of these agents inhibited TXA₂ formation by platelets from arachidonate. Nitroglycerin did not show any effect on PGI₂ and TXA₂ formation in the coupled system and on TXA₂ formation by platelets. In contrast with these compounds, in spite of showing no inhibitory effect on TXA₂ formation by platelets alone, 2-nicotinamidoethyl nitrate (SG-75) increased PGI₂ and decreased TXA₂ in the coupled system. It is suggested that SG-75 accelerated the conversion of PGH₂ to PGI₂ so that smaller amounts of TXA₂ was produced in the coupled system.